WASATCH ADVISORS LP 13D and 13G filings for Sangamo Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
2025-01-07 6:47 pm Sale | 2024-12-31 | 13G | Sangamo Therapeutics, Inc. SGMO | WASATCH ADVISORS LP | 13,993,410 6.600% | -10,900,819 (-43.79%) | Filing |
2024-04-05 3:59 pm Purchase | 2024-04-05 | 13G | Sangamo Therapeutics, Inc. SGMO | WASATCH ADVISORS LP | 24,894,229 11.900% | 12,496,305 (+100.79%) | Filing |
2024-02-09 12:17 pm Sale | 2024-02-09 | 13G | Sangamo Therapeutics, Inc. SGMO | WASATCH ADVISORS LP | 12,397,924 7.000% | -5,588,857 (-31.07%) | Filing |
2023-10-10 3:09 pm Purchase | 2023-10-10 | 13G | Sangamo Therapeutics, Inc. SGMO | WASATCH ADVISORS LP | 17,986,781 10.160% | 5,336,027 (+42.18%) | Filing |
2023-02-09 4:21 pm Purchase | 2023-02-09 | 13G | Sangamo Therapeutics, Inc. SGMO | WASATCH ADVISORS LP | 12,650,754 7.700% | 1,689,772 (+15.42%) | Filing |
2022-02-10 5:42 pm Purchase | 2022-02-11 | 13G | Sangamo Therapeutics, Inc. SGMO | WASATCH ADVISORS LP | 10,960,982 7.500% | 888,601 (+8.82%) | Filing |
2021-02-11 2:09 pm Purchase | 2021-02-11 | 13G | Sangamo Therapeutics, Inc. SGMO | WASATCH ADVISORS LP | 10,072,381 7.100% | 2,585,364 (+34.53%) | Filing |
2020-02-10 2:10 pm Purchase | 2020-02-10 | 13G | Sangamo Therapeutics, Inc. SGMO | WASATCH ADVISORS LP | 7,487,017 6.500% | 3,622,389 (+93.73%) | Filing |